On the occasion of a Research & Development day organized by Moderna, Stéphane Bancel presented Thursday the 37 projects currently under development in the company, reports
Les Echos
.
“Moderna is not the Covid-19 vaccine company.
In any case, not only ”declared the French boss of this American company at the origin of one of the first vaccines against the coronavirus.
Among these many projects, we find in particular a therapeutic vaccine against cancer, a vaccine against the Zika virus, HIV-AIDS, CMV (cytomegalovirus), RSV (respiratory syncytial virus) but also a single vaccine effective both against influenza and Covid-19.
“The population will keep the epidemic in mind and will be much more willing to recurrent vaccination,” added Stéphane Bancel.
A market estimated at 5 or 6 billion dollars
The boss of Moderna estimates the market for a combined influenza / Covid-19 vaccine at nearly $ 5 or 6 billion. This combined vaccine project, currently in Phase 1, would also be less restrictive and less expensive. If it were to be put on the market, its sales would thus be added to the turnover of the company, which in 2021 should be 20 billion euros according to the latest estimates related to the sale of their vaccine. against Covid-19.
This record turnover therefore explains the large number of ongoing projects of this company known for its messenger RNA technology.
During this R & D day, an update on the effectiveness of the vaccine against Covid-19 was also carried out.
The company then recalled that regardless of age, Moderna's vaccine would be the most immunogenic, according to independent studies.
If its effectiveness decreases in the face of variants, it does not drop below 75%.
The vaccine RNA was not changed in anticipation of the third dose.
Health
Vaccination: Guillain-Barré syndrome is believed to be a "very rare" side effect of AstraZeneca
Health
Vaccination: Are we to fear long-term adverse effects of messenger RNA vaccines?
Health
Flu
Moderna
Anti-covid vaccine